Potentials for drug savings in the generic sector experience accross Europe"
Innovation brings value to healthcare – but drives drug cost!
Affordability of health care – a Pan-European dilemma
Potential for savings using generics
World market growth rate continues to slide
Even if generics are growing fast, original brand no longer protected is larger in top 5 Europe
USA – Generics dominate the unprotected market volume
In dispensed Rx, generic erosion is usually 70 -80% after 12 weeks
UK – a true generics market with high penetration and low prices
Germany- a strong generic market driven by the payer
France – a growing generic market in its very early stages with prices still currently high
Switching to generics varies between countries and molecules
Issues to achieve generic penetration
Generics also show very different price levels …
Increased awareness where the money ends – market price is far below Drug Tariff in UK
The power of discounts
Countries are using different generics strategies due to differences in circumstances
The UK achieved these savings via specific policy infrastructure
The outlook – significant new molecules will go off patent in the next 5 years.
Summary
Potentials for drug savings in the generic sector experience accross Europe"